IP Library › Granted Patent US 12,618,057
Granted Patent B2
US 12,618,057 · App. 17/603,326 · Granted May 5, 2026

Method of purifying botulinum toxin

Inventors: Jae Young Kim (Seoul, KR); Jeong Sun Nam (Seoul, KR); Seungho Kim (Seoul, KR); Seung Kwan Choi (Gyeonggi-do, KR); Bum Jin Yun (Seoul, KR); Jin Hee Choi (Seoul, KR)
Assignee: JETEMA CO., LTD.
C12N9/52C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,618,057
App. No.
17/603,326
Granted
May 5, 2026
Kind
B2
Abstract

Disclosed is a method of purifying a botulinum toxin including (a) pre-treating a culture solution containing a botulinum toxin, (b) purifying the pre-treated botulinum toxin using anion exchange chromatography and (c) purifying the botulinum toxin using cation exchange chromatography. The method is capable of purifying a botulinum toxin with high purity and activity using a simple process including anion exchange chromatography and cation exchange chromatography, and is thus useful for botulinum toxin production.

Claims (5)

1 . A two column chromatography method of purifying a 900 kDa botulinum toxin complex, comprising:

(a) pre-treating a culture solution containing a botulinum toxin;

(b) preparing the pre-treated botulinum toxin from step (a) by dissolving it in 30-70 mM sodium phosphate buffer at pH 5.5-6.5 and injecting it into an anion exchange chromatography column to bind the botulinum toxin to the anion exchange chromatography medium at a pH higher than an isoelectric point (PI) of botulinum toxin, said anion exchange chromatography column comprising a column packed with a resin containing a methacrylic bead with a particle size of 65 μm comprising a quaternary ammonium (Q) functional group, wherein the ion exchange capacity of the column is 0.25±0.05 meq/mL, and the DBC (dynamic binding capacity) of the column is 149 mg/mL based on BSA, and separating the botulinum toxin, which is bound to the anion exchange chromatography medium, by elution with a 30 to 70 mM sodium phosphate buffer having a pH of 5.5 to 6.5 comprising 0.4 to 0.6M sodium chloride; and

(c) preparing the botulinum toxin from step (b) by dissolving it in 15 to 25 mM sodium citrate buffer at pH 4.0 to 5.0 and injecting it into a cation exchange chromatography column to bind the botulinum toxin to the cation exchange chromatography medium, said cation exchange chromatography column comprising a column packed with a resin that contains a sulfopropyl functional group, has a 6% spherical, cross-linked agarose matrix form, and has a DBC of 55 mg/mL based on ribonuclease A and a particle size of 34 μm, and separating 900 kDa botulinum toxin complex from the solution which is bound to the cation exchange chromatography medium, by elution with a 15 to 25 mM sodium citrate buffer having a pH of 4.0 to 5.0 comprising 0.4 to 0.6M sodium chloride.

2 . The method according to claim 1 , wherein the purified botulinum toxin is botulinum toxin A having a purity of 95% or more.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2021
From: KIM, JAE YOUNG; NAM, JEONG SUN; KIM, SEUNGHO; CHOI, SEUNG KWAN; YUN, BUM JIN; CHOI, JIN HEE
To: JETEMA CO., LTD.
Reel/Frame 057892/0838 →
Priority Claims (1)
KR 10-2019-0043868 · Apr 15, 2019 · national
Continuity (1)
Related Publication 20220186201A1 · Jun 16, 2022
References Cited (36)
US 7354740B2 · Xiang et al. · 2008 [cited by applicant]
US 7452697B2 · Luo et al. · 2008 [cited by applicant]
US 20030008367A1 · Oguma · 2003 [cited by applicant]
US 20180251741A1 · Kim et al. · 2018 [cited by applicant]
CN 106117325A · 2016 [cited by applicant]
JP 2011074025A · 2011 [cited by applicant]
KR 1020070116710A · 2007 [cited by applicant]
KR 1020180037420A · 2008 [cited by applicant]
KR 1020090120222A · 2009 [cited by applicant]
KR 1020120099431A · 2012 [cited by applicant]
KR 1020120105417A · 2012 [cited by applicant]
KR 101339349B1 · 2013 [cited by applicant]
KR 1020170062694A · 2017 [cited by applicant]
RU 2230325C2 · 2004 [cited by applicant]
RU 2627159C2 · 2017 [cited by applicant]
RU 2663136C2 · 2018 [cited by applicant]
WO WO2006042542A2 · 2006 [cited by applicant]
WO 2011008713A1 · 2011 [cited by applicant]
WO 2011050072A1 · 2011 [cited by applicant]
WO 2018065972A1 · 2018 [cited by applicant]
WO 2010127258A1 · 2020 [cited by applicant]
“Food Products: Methods for Detection of Botulinic Toxins and Clostridium Botulinum”, Interstate Standard, 2010, Official Edition, Publisher: IPK Standards Publishing House. [cited by applicant]
English Translation, “Food Products: Methods for the Detection of Botulinic Toxins Clostridium Botulinum”, Interstate Standard, 2010, Offical Edition, Publisher: IPK Standards Publishing House. [cited by applicant]
Office Action issued on Aug. 15, 2022 in counterpart Russian Patent Application No. 2021128381, Aug. 15, 2022. [cited by applicant]
English Translation of Office Action issued in counterpartRussian Patent Application No. 2021128381, Aug. 15, 2022. [cited by applicant]
Search Report issued on Aug. 15, 2022 in counterpart Russian Patent Application No. 2021128381, Aug. 15, 2022. [cited by applicant]
Johnson, S.K., et al., “Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris”, Protein & Expression Purification, 2003,… [cited by applicant]
Kannan, K., et al., “Methods Development for the Biochemical Assessment of Neurobloc TM (Botulinum Toxin Type B)”, Movement Disorders, 2000, pp. 18-26, vol. 15, No. 2, Publisher: Movement Disorders Society. [cited by applicant]
Schantz, E., et al., “Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine”, Microbiological Reviewss, 1992, pp. 80-99, vol. 56, No. 1, Publisher: American Society for Microbiology. [cited by applicant]
Schmidt, J., et al., “Purification of Type E Botulinum Neurotoxin by High-Performance Ion Exchange Chromatography”, Analytical Biochemistry, 1986, pp. 213-219, vol. 156. [cited by applicant]
Zhou, L., et al., “Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation 5 Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain”, Biochemist… [cited by applicant]
EESR Issued in counterpart European Patent Application No. 20791856.6, Dec. 19, 2022. [cited by applicant]
Notice of Allowance issued in counterpart Korean Patent Application No. 10-2020-0044718, Dec. 26, 2022. [cited by applicant]
English Translation of Notice of Allowance Issued in counterpart Korean Patent Application No. 10-2020-0044718, Dec. 26, 2022. [cited by applicant]
Notice of Allowance Issued in Korean Patent Application No. 10-2020-0044716 on Mar. 23, 2023. [cited by applicant]
English Translation of Notice of Allowance Issued in Korean Patent Application No. 10-2020-0044716 on Mar. 23, 2023. [cited by applicant]